With a total investment of 730 million yuan, a therapeutic monoclonal antibody pilot plant was built which offers a scale of up to 2000 L for the production of monoclonal antibodies for clinical tests and will be further scaled up to 80.000L, enough to produce 3 tons of monoclonal antibody protein (anti tumor) per year. The plant is located in Fujian’s Sanming Hi-Tech Zone.

China Bio news release, August 29, 2015

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny